Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations


Gridelli, C., Manegold, C., Mali, P., Reck, M., Portalone, L., Castelnau, O., Stahel, R., Betticher, D., Pless, M., Pons, J.T., Aubert, D., Burillon, J.P., Parlier, Y. and De Marinis, F. (2004) Oral Vinorelbine Given as Monotherapy to Advanced, Elderly NSCLC Patients: A Multicentre Phase II Trial. European Journal of Cancer, 40, 2424-2431.

has been cited by the following article:

  • TITLE: Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type

    AUTHORS: Amen Hamdy Zaky, Ahmed Refaat Abd Elzaher, Ola Nabih

    KEYWORDS: Lung Cancer, Maintenance Chemotherapy, Vinorelbine, EGFR-Wild Type

    JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.12, December 10, 2019

    ABSTRACT: Background: This study was performed to evaluate the efficacy and safety of switch maintenance therapy with oral vinorelbine in advanced non-small cell lung cancer (NSCLC) with adenocarcinoma limited to epidermal growth factor receptor (EGFR) wild type. Materials and Methods: In this single randomized trial, patients with advanced stage (IIIB and IV) NSCLC with adenocarcinoma EGFR wild-type status, treated with 6 cycles of platinum based chemotherapy. Patients did not show progression after first-line chemotherapy were randomly assigned to receive switch maintenance with vinorelbine (80 mg/m2, day 1, 8) (group I) or the best supportive care until disease progression (group II). Results: The median progression free survival (PFS) was 9.7 months for group I versus 5.7 months for group II with statistically significant difference between both groups [HR = 1.15; 95% CI 1.19 to 1.49; P value = 0.002], while the median overall survival (OS) was 13.2 months for group I versus 11.9 months for group II with no statistically significant differences between both groups [HR = 1.24; 95% CI 1.05 to 1.46; P value = 0. 3]. The patients who received oral vinorelbine had tolerable toxicity profile. Conclusion: Switch maintenance therapy with oral vinorelbine, though improve PFS, did not improve OS in patients with NSCLC with adenocarcinoma EGFR wild type.